A pioneer in regenerative technologies; GIOSTAR announced today that they will be conducting clinical trials for Diabetes type-2 for using advanced stem cell therapy with the approval of United States Food and Drug Administration. Chairman and one of the founders of GIOSTAR, Dr. Anand Srivastava initiated the process and now scientists are focused on the advanced techniques to fight with this disease such as by differentiating stem cells and enabling them for insulin production.
According to a recent report by the Centers for Disease Control and Prevention (CDC), more than 100 million US adults are now diabetic. The most common of which is type 2. According to the CDC, 90% of patients have type 2. Unhealthy habits, sedentary lifestyle, environmental factors, abnormal cholesterol level, and high-calorie food are the risk factors and contributes to this metabolic syndrome.
In recent years, the relevant patient-care expense has catapulted due to an increased incidence rate. The “American Association of Diabetes” gave an estimated figure of $327 billion, covering direct medical costs and reduced productivity in their 2017 assessment.
The typical approach to fight this disease is by pharmaceutical products. This procedure has many constraints and side effects as well. As there are multiple harmful side effects of these pharmaceutical products, with stem cell therapy there will only mild post-treatment undesirable effects limited to nausea, headache or mild fever. Stem cell therapy is a lasting cure as compared to those drugs which only masks the early signs of diabetes. Stem cell therapy offers many benefits and is the feasible source of replacement of cells to treat the problem.
More than 150 clinical trials recorded on the official website of National Institutes of Health (NIH). This data has unveiled the therapeutic benefits of stem cells for treating diabetes.
To date, hundreds of trials on stem cell therapy have been conducted and they all gave a positive response. More than 150 trials are listed on the website of the National Institutes of Health (NIH). All these trials have shown the potential benefits of this revolutionary method. Patients treated with this therapy showed positive results and improved response to insulin. Patients are satisfied with this miracle treatment.
A study conducted by Dr. Srivastava emphasized the therapeutic potential of mesenchymal stem cells (MSCs); multipotent stromal cells. MSCs are safe, relatively increased differentiation capacity and have a high paracrine ability. They have several plus points as they can limit cell death, reduce oxidative stress. It further reduces insulin resistance because of its high paracrine ability.
These mesenchymal stem cells (MSCs) can act as a source for anti-inflammatory cytokines for the body that further generate cells with an ability to produce insulin.
According to Srivastava, stem cell therapeutics is a permanent alternative for typical methods to treat diabetes type 2. However, more extensive research is required for further advancement and a good scientific basis. Unproven stem cell treatments must be avoided. In the future, hopefully, with the advancement of methods supported by scientific research quality of life will be improved.
To stay safe, please confirm that the stem cell treatment you are considering is either:
- Under the study of an Investigational New Drug Application (IND).